The pharmaceutical community is excited about Retatrutide 120 , a twin-action therapy showing impressive results in early research. This groundbreaking compound, a GLP-1 activator alongside a glucose-dependent insulinotropic compound, appears to effectively lower body size and enhance metabolic health . Experts are suggesting that it may offer a re